Abstract:RNAs with 5′‐triphosphate (ppp) are detected in the cytoplasm principally by the innate immune receptor RIG‐I, whose activation triggers a Type I interferon response. Cellular RNAs undergo post‐transcriptional modifications which ensures that self RNAs do not carry 5′ppp and/or blunt‐ends. We carried out a thorough biochemical characterization of RIG‐I complexes with RNAs carrying various end‐modifications as well as measured the effect of these end‐modifications on their signaling activity. We find that discrimination of RNA ligands occurs at multiple stages and signaling RNAs have high affinity and ATPase turnover rate and thus a high k atpase / K d . Our studies reveal that the autoinhibitory interface between CARD2 (second CARD) and Hel2i (Helicase 2 insertion domain) plays a critical role in RNA selectivity, wherein this interface acts as a “gate” that prevents cellular RNAs from generating productive complexes that can signal. It is thought that self RNAs like mRNAs are not recognized by RIG‐I because 5′ppp is capped by the addition of a 7‐methyl guanosine (m7G) (Cap‐0) and the 5′‐end nucleotide ribose is 2′‐O‐methylated (Cap‐1). We provide a structural and mechanistic basis for the exact roles of capping and 2′‐O‐methylation in evading RIG‐I recognition using enzymatic assays, X‐ray crystallography and cell‐based signaling studies. Surprisingly, we find that Cap‐0 and 5′ppp dsRNA have similar binding affinities, activate RIG‐I's ATPase to the same extent, and shows the same cellular signaling response. Three new crystal structures of RIG‐I complexes with dsRNA bearing 5′OH, 5′ppp, and 5′Cap‐0 reveal that RIG‐I accommodates m7G in a cavity created through conformational changes in helicase‐motif IVa without perturbing the triphosphate interactions. In contrast, Cap‐1 modifications abrogate RIG‐I signaling through a mechanism involving the H830 residue, wherein 2′‐O‐methylation works synergistically with m7G capping to weaken RNA affinity and ATPase activity. Our work provides new structural insights into the host and viral immune evasive mechanisms from RIG‐I explaining the complexity of cap structures over evolution. Support or Funding Information This work was supported by NIH grant GM111959 to Joseph Marcotrigiano and Smita S Patel.

HDX-MS Reveals Dysregulated Checkpoints That Compromise Discrimination Against Self RNA During RIG-I Mediated Autoimmunity.

A Loosened Gating Mechanism of RIG-I Leads to Autoimmune Disorders.

Structural and Mechanistic Basis for Self Versus Non‐self RNA Discrimination by the Innate Immune Receptor RIG‐I

Structural and biochemical studies of RIG-I antiviral signaling

RIG-I Uses an ATPase-Powered Translocation-Throttling Mechanism for Kinetic Proofreading of RNAs and Oligomerization

E3 Ligase FBXW7 is Critical for RIG-I Stabilization During Antiviral Responses

Reciprocal regulation of RIG-I and XRCC4 connects DNA repair with RIG-I immune signaling

Kinetic discrimination of self/non-self RNA by the ATPase activity of RIG-I and MDA5

A conserved isoleucine in the binding pocket of RIG-I controls immune tolerance to mitochondrial RNA

Phosphorylation of RIG-I by casein kinase II inhibits its antiviral response.

Cyclophilin A-regulated Ubiquitination is Critical for RIG-I-mediated Antiviral Immune Responses.

Rig-I−/− Mice Develop Colitis Associated with Downregulation of Gαi2

Retinoic acid inducible gene-I, more than a virus sensor

The molecular mechanism of RIG‐I activation and signaling

Thymidine phosphorylase facilitates retinoic acid inducible gene-I induced endothelial dysfunction

Immune Regulator Retinoic Acid-Inducible Gene I (RIG-I) in the Pathogenesis of Cardiovascular Disease

A Viral Deamidase Targets the Helicase Domain of RIG-I to Block RNA-Induced Activation.

A Cell-Based Screen Identifies HDAC Inhibitors as Activators of RIG-I Signaling

Mutant RIG-I enhances cancer-related inflammation through activation of circRIG-I signaling

Is the Association of the Rare rs35667974 IFIH1 Gene Polymorphism With Autoimmune Diseases a Case of RNA Epigenetics?

Phosphorylation-mediated negative regulation of RIG-I antiviral activity